{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:13:18Z","timestamp":1788484398090,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.revmed.2026.05.003","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T20:47:18Z","timestamp":1781815638000},"page":"490-499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autosomal dominant polycystic kidney disease: Current perspectives in 2026"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9089-7656","authenticated-orcid":false,"given":"Maude","family":"Pichette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2695-0894","authenticated-orcid":false,"given":"Meyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Cornec-Le Gall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2026.05.003_bib0290","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1681\/ASN.2018050493","article-title":"Prevalence estimates of polycystic kidney and liver disease by population sequencing","volume":"29","author":"Lanktree","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0295","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/ndt\/gfw240","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union","volume":"32","author":"Willey","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2026.05.003_bib0300","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD Score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0305","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.kint.2024.07.010","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary","volume":"107","author":"Torres","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2026.05.003_bib0310","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2026.05.003_bib0315","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1152\/physrev.00018.2024","article-title":"Physiologic mechanisms underlying polycystic kidney disease","volume":"105","author":"Boletta","year":"2025","journal-title":"Physiol Rev"},{"key":"10.1016\/j.revmed.2026.05.003_bib0320","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2025.0310","article-title":"Autosomal dominant polycystic kidney disease: a review","volume":"333","author":"Chebib","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2026.05.003_bib0325","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0330","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ajhg.2022.06.013","article-title":"Monoallelic pathogenic ALG5 variants cause atypical polycystic kidney disease and interstitial fibrosis","volume":"109","author":"Lemoine","year":"2022","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.revmed.2026.05.003_bib0335","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1172\/JCI90129","article-title":"Isolated polycystic liver disease genes define effectors of polycystin-1 function","volume":"127","author":"Besse","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.revmed.2026.05.003_bib0340","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1681\/ASN.0000000613","article-title":"Characterization of the cystic phenotype associated with monoallelic ALG8 and ALG9 pathogenic variants","volume":"36","author":"Jawaid","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0345","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1681\/ASN.2019030298","article-title":"ALG9 mutation carriers develop kidney and liver cysts","volume":"30","author":"Besse","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0350","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.revmed.2026.05.003_bib0355","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.revmed.2026.05.003_bib0360","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ajhg.2021.11.016","article-title":"Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype","volume":"109","author":"Senum","year":"2022","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.revmed.2026.05.003_bib0365","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.kint.2023.07.021","article-title":"Certain heterozygous variants in the kinase domain of the serine\/threonine kinase NEK8 can cause an autosomal dominant form of polycystic kidney disease","volume":"104","author":"Claus","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2026.05.003_bib0370","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0375","doi-asserted-by":"crossref","first-page":"ii17","DOI":"10.1093\/ckj\/sfaf331","article-title":"Genetic testing in autosomal dominant polycystic kidney disease: why it matters in 2025","volume":"18","author":"Cornec-Le Gall","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.revmed.2026.05.003_bib0380","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0385","doi-asserted-by":"crossref","first-page":"e138724","DOI":"10.1172\/jci.insight.138724","article-title":"The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD","volume":"5","author":"Lavu","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.revmed.2026.05.003_bib0390","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0395","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2026.05.003_bib0400","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","article-title":"Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease","volume":"95","author":"Yu","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2026.05.003_bib0405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mayocpiqo.2022.12.005","article-title":"Changes in kidney and liver volumes in patients with autosomal dominant polycystic kidney disease before and after dialysis initiation","volume":"7","author":"Suwabe","year":"2023","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.revmed.2026.05.003_bib0410","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.kint.2025.05.036","article-title":"New insights in the pathophysiology and treatment of hypertension in autosomal dominant polycystic kidney disease","volume":"108","author":"Dumont","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2026.05.003_bib0415","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2967\/jnumed.117.199448","article-title":"18 F-FDG PET\/CT in autosomal dominant polycystic kidney disease patients with suspected cyst infection","volume":"59","author":"Pijl","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.revmed.2026.05.003_bib0420","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ndt\/gfv452","article-title":"Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review","volume":"32","author":"Lantinga","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2026.05.003_bib0425","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.ackd.2010.01.005","article-title":"Evaluation and management of pain in autosomal dominant polycystic kidney disease","volume":"17","author":"Hogan","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.revmed.2026.05.003_bib0430","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/ndt\/gfac158","article-title":"Multidisciplinary management of chronic refractory pain in autosomal dominant polycystic kidney disease","volume":"38","author":"van Luijk","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2026.05.003_bib0435","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0272-6386(12)80922-X","article-title":"Renal stone disease in autosomal dominant polycystic kidney disease","volume":"22","author":"Torres","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.revmed.2026.05.003_bib0440","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1478-3231.2010.02247.x","article-title":"Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases","volume":"31","author":"Van Keimpema","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.revmed.2026.05.003_bib0445","first-page":"1282","article-title":"Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease","volume":"26","author":"Sherstha","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2026.05.003_bib0450","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/cpt.1553","article-title":"Estrogen-containing oral contraceptives are associated with polycystic liver disease severity in premenopausal patients","volume":"106","author":"Van Aerts","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.revmed.2026.05.003_bib0455","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/liv.14986","article-title":"Estrogens in polycystic liver disease: a target for future therapies?","volume":"41","author":"Aapkes","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.revmed.2026.05.003_bib0460","doi-asserted-by":"crossref","first-page":"e0257606","DOI":"10.1371\/journal.pone.0257606","article-title":"Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: a systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Suwabe","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.revmed.2026.05.003_bib0465","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1474-4422(11)70109-0","article-title":"Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis","volume":"10","author":"Vlak","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0470","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/ndt\/gfac027","article-title":"Diagnosis and risk factors for intracranial aneurysms in autosomal polycystic kidney disease: a cross-sectional study from the Genkyst cohort","volume":"37","author":"Lef\u00e8vre","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2026.05.003_bib0475","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2215\/CJN.14691218","article-title":"Presymptomatic screening for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease","volume":"14","author":"Sanchis","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0480","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.3171\/2020.4.JNS20544","article-title":"Lack of impact of polycystic kidney disease on the outcome of aneurysmal subarachnoid hemorrhage: a matched case-control study","volume":"134","author":"Nurmonen","year":"2021","journal-title":"J Neurosurg"},{"key":"10.1016\/j.revmed.2026.05.003_bib0485","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrneph.2015.128","article-title":"Vascular complications in autosomal dominant polycystic kidney disease","volume":"11","author":"Perrone","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0490","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3109\/14767058.2015.1019458","article-title":"Pregnancy outcomes in autosomal dominant polycystic kidney disease: a case-control study","volume":"29","author":"Wu","year":"2016","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.revmed.2026.05.003_bib0495","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1053\/j.ajkd.2016.07.023","article-title":"Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial","volume":"68","author":"Amro","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.revmed.2026.05.003_bib0500","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100021","article-title":"Prescribed water intake in autosomal dominant polycystic kidney disease","volume":"1","author":"Rangan","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.revmed.2026.05.003_bib0505","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2215\/CJN.00790209","article-title":"A case for water in the treatment of polycystic kidney disease","volume":"4","author":"Torres","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0510","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2215\/CJN.0000000000000326","article-title":"Polycystic kidney disease diet: what is known and what is safe","volume":"19","author":"Chebib","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2026.05.003_bib0515","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2026.05.003_bib0520","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2026.05.003_bib0525","doi-asserted-by":"crossref","first-page":"109524","DOI":"10.1016\/j.cellsig.2020.109524","article-title":"Role of oxygen and the HIF-pathway in polycystic kidney disease","volume":"69","author":"Buchholz","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.revmed.2026.05.003_bib0530","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","article-title":"HIF-1\u03b1 promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease","volume":"94","author":"Kraus","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2026.05.003_bib0535","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.kint.2025.06.005","article-title":"Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)","volume":"109","author":"Babitt","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2026.05.003_bib0540","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2026.05.003_bib0545","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2026.05.003_bib0550","article-title":"Interventions for preventing the progression of autosomal dominant polycystic kidney disease","volume":"10","author":"St Pierre","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2026.05.003_bib0555","series-title":"Jinarc (tolvaptan): EPAR product information","year":"2024"},{"key":"10.1016\/j.revmed.2026.05.003_bib0560","doi-asserted-by":"crossref","first-page":"e135700","DOI":"10.1172\/jci.insight.135700","article-title":"Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis","volume":"5","author":"Kashyap","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.revmed.2026.05.003_bib0565","doi-asserted-by":"crossref","first-page":"14395","DOI":"10.1038\/ncomms14395","article-title":"microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism","volume":"8","author":"Hajarnis","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.revmed.2026.05.003_bib0570","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/ndt\/gfaf061","article-title":"SGLT2 inhibition for patients with ADPKD\u00a0\u2013\u00a0closing the evidence gap","volume":"40","author":"M\u00fcller","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2026.05.003_bib571","unstructured":"Gansevoort R., Chapman, A., Chebib, F.T., Cornec-Le Gall, E., Hiemstra, T., Isaka, Y., et al. Study design of a global Phase 3 trial evaluating the efficacy and safety of farabursen, an anti-miR-17 oligonucleotide, in patients with ADPKD. Focussed Oral, presented at 63rd ERA Congress 2026, Glasgow UK."}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866326005709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866326005709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:41:25Z","timestamp":1788482485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866326005709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0248866326005709"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2026.05.003","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autosomal dominant polycystic kidney disease: Current perspectives in 2026","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2026.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}